<?xml version="1.0" encoding="UTF-8" ?><!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
	"http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" >
<html><head><title>Side-by-side differences</title><link rel="stylesheet" type="text/css" href="/archive/history.css" /><link rel="stylesheet" type="text/css" href="/archive/sdiff.css" /><script type="text/javascript" src="/archive/common.js"></script><script type="text/javascript" src="/archive/sdiff.js"></script><style>table.sdiff div.sdl0 { margin-left: 0em; }
table.sdiff div.sdl1 { margin-left: 2em; }
table.sdiff div.sdl2 { margin-left: 4em; }
table.sdiff div.sdl3 { margin-left: 6em; }
table.sdiff div.sdl4 { margin-left: 8em; }
table.sdiff div.sdl5 { margin-left: 10em; }
table.sdiff div.sdl6 { margin-left: 12em; }
table.sdiff div.sdl7 { margin-left: 14em; }
table.sdiff div.sdl8 { margin-left: 16em; }
table.sdiff div.sdl9 { margin-left: 18em; }
table.sdiff div.sdl10 { margin-left: 20em; }
table.sdiff div.sdl11 { margin-left: 22em; }
table.sdiff div.sdl12 { margin-left: 24em; }
table.sdiff div.sdl13 { margin-left: 26em; }
table.sdiff div.sdl14 { margin-left: 28em; }
table.sdiff div.sdl15 { margin-left: 30em; }
table.sdiff div.sdl16 { margin-left: 32em; }
table.sdiff div.sdl17 { margin-left: 34em; }
table.sdiff div.sdl18 { margin-left: 36em; }
table.sdiff div.sdl19 { margin-left: 38em; }
</style></head><body class="sdiff">
<div class="navTop"><table class="navTopTriptych"><tr><td class="navTopTriptychL"><img src="/archive/ctgov_logo_ttl.gif" alt="ClinicalTrials.gov" width="360" height="47" /></td><td class="navTopTriptychC" style="background-image: url(/archive/ctgov_logo_ttm.gif)" /><td class="navTopTriptychR"><img src="/archive/ctgov_logo_ttr.gif" alt="Linking patients to medical research" width="314" height="47" /></td></tr></table></div>
<div id="sdiff-links" class="navLinks" /><div id="navLinks" class="navLinks"><a href="/archive/NCT00308100">&#8592; History of this study</a><a href="http://clinicaltrials.gov/show/NCT00308100">&#8593; Current version of this study</a></div><form><div id="sdiff-js-menu" style="display: none"><div><input type="checkbox" id="sdiff-HideUnch-cb" name="sdiff-HideUnch" value="true" onclick="SDiffUpdateHideUnch(&#39;sdiff-HideUnch-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideUnch(&#39;sdiff-HideUnch-cb&#39;)"> Hide unchanged portions (except top/bottom lines)</span></div><div><input type="checkbox" id="sdiff-HideNonMain-cb" name="sdiff-HideNonMain" value="true" onclick="SDiffUpdateHideNonMain(&#39;sdiff-HideNonMain-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideNonMain(&#39;sdiff-HideNonMain-cb&#39;)"> Hide non-essential portions (contact info, locations, etc.)</span></div><div style="display:none"><input type="checkbox" id="sdiff-HideKey-cb" name="sdiff-HideKey" value="true" onclick="SDiffUpdateHideKey(&#39;sdiff-HideKey-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideKey(&#39;sdiff-HideKey-cb&#39;)"> Hide key</span></div></div><h1>Changes to NCT00308100 on 2006_08_31</h1><div id="sdiff-key"><div id="sdiff-key-mb"><img id="sdiff-key-minmax" onclick="SDiffToggleHideKey(&#39;sdiff-HideKey-cb&#39;)" src="/archive/minmax.gif" alt="[+/-]" width="16" height="16" style="display:none" /><h2>Key</h2></div><img id="sdiff-key-img" src="/archive/sdiff-key.gif" alt="Key" /></div><div class="sdiff-changedesc"><em>Type of info changed: </em>Protocol, Misc.</div><div class="sdiff-view" id="sdiff-full" style="display: none"><table class="sdiff navLinks"><colgroup><col id="h-col" /><col id="a-col" /><col id="b-col" /></colgroup><tr><th class="sdiff-h" /><th class="sdiff-a"><div class="sdiff-prev"><a href="/archive/NCT00308100/2006_08_30/changes" title="Show changes from prior version to this one"><img src="/archive/prev.gif" alt="[Previous]" width="23" height="19" /></a></div><h2>Before</h2><h3><a href="/archive/NCT00308100/2006_08_30">(Updated 2006_08_30)</a></h3></th><th class="sdiff-b"><div class="sdiff-next"><a href="/archive/NCT00308100/2008_05_01/changes" title="Show changes from this version to next one"><img src="/archive/next.gif" alt="[Next]" width="23" height="19" /></a></div><h2>After</h2><h3><a href="/archive/NCT00308100/2006_08_31">(Updated 2006_08_31)</a></h3></th></tr>
<tr class="sdiff-unc" id="sdiff-chunk-f1"><td class="sdiff-h">1</td>
<td class="sdiff-a"><img id="sdiff-collapse-f0A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><img id="sdiff-collapse-f0A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-f0A-cdiv" class="sdiff-collapsed" title="The middle 37 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none"></div><div id="sdiff-collapse-f0A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  BeijingFKP</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  Beijing Fresenius Kabi Pharmaceutical Co</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  BFP502</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT00308100</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Hydroxyethyl Starch (130/0.4) for Intravascular Volume Therapy in Liver Transplantation</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  A Multicenter, Randomized, Open-Label, Parallel-Group, Albumin-Controlled Phase IV Study to Evaluate the Efficacy and Safety of Hydroxyethyl Starch (130/0.4) for Intravascular Volume Therapy in Patients Undergoing Liver Transplantation</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Beijing Fresenius Kabi Pharmaceutical Co</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  China: State Food and Drug Administration</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
</div><div class="sdl2 sds">&lt;textblock&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f0B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><img id="sdiff-collapse-f0B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-f0B-cdiv" class="sdiff-collapsed" title="The middle 37 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none"></div><div id="sdiff-collapse-f0B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  BeijingFKP</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  Beijing Fresenius Kabi Pharmaceutical Co</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  BFP502</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT00308100</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Hydroxyethyl Starch (130/0.4) for Intravascular Volume Therapy in Liver Transplantation</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  A Multicenter, Randomized, Open-Label, Parallel-Group, Albumin-Controlled Phase IV Study to Evaluate the Efficacy and Safety of Hydroxyethyl Starch (130/0.4) for Intravascular Volume Therapy in Patients Undergoing Liver Transplantation</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Beijing Fresenius Kabi Pharmaceutical Co</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  China: State Food and Drug Administration</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
</div><div class="sdl2 sds">&lt;textblock&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f2"><td class="sdiff-h">2</td>
<td class="sdiff-a"><div class="sdl3">End-stage liver disease is one of the major diseases leading to death. Liver transplantation is an effective method to recover patients&amp;#8217; liver function, thus saving their lives and improving their quality of life. Serious disorders of fluid balance exist in <span class="sdwd">end</span> <span class="sdwd">stage</span>  cirrhosis patients undergoing liver transplantation. Such abnormalities could cause or worsen cardiovascular and pulmonary dysfunction, thus making perioperative management more difficult. </div>
</td>
<td class="sdiff-b"><div class="sdl3">End-stage  liver  disease  is  one  of  the  major  diseases  leading  to  death.  Liver  transplantation  is  an  effective  method  to  recover  patients&amp;#8217;  liver  function,  thus  saving  their  lives  and  improving  their  quality  of  life.  Serious  disorders  of  fluid  balance  exist  in    <span class="sdwa">end-stage</span> cirrhosis  patients  undergoing  liver  transplantation.  Such  abnormalities  could  cause  or  worsen  cardiovascular  and  pulmonary  dysfunction,  thus  making  perioperative  management  more  difficult.  </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f3"><td class="sdiff-h">3</td>
<td class="sdiff-a"><img id="sdiff-collapse-f40A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f40&#39;)" style="display:none" /><img id="sdiff-collapse-f40A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f40&#39;)" style="display:none" /><div class="sdl3">  </div>
<div id="sdiff-collapse-f40A-cdiv" class="sdiff-collapsed" title="The middle 38 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f40&#39;)" style="display:none"></div><div id="sdiff-collapse-f40A-ediv" class="sdiff-expanded"><div class="sdl3">  Albumin and blood plasma are conventionally used as plasma volume expanders in clinical practice. The focus of debate for many years has been whether albumin should be used for volume replacement in critically ill patients.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Voluven (130/0.4) is a medium molecular weight hydroxyethyl starch (HES) produced by Beijing Fresenius Kabi Pharmaceutical Co., Ltd. It is a novel HES preparation with optimized molecular weight and molecule distribution, has a lower degree of substitution (DS) (0.4), and a narrower molecular distribution profile (C2/C6) than other available HES specifications which make it more suitable for volume replacement therapy. Some studies have revealed that Voluven (130/0.4) has a comparable efficacy with HAES-steril (average molecular weight 200.000 dalton, degree of substitution 0.5). Because of its improved pharmacological profile, Voluven (130/0.4) is used to avoid capillary vessel leakage and improve oxygenation of tissues. In addition, Voluven (130/0.4) does not accumulate in plasma or tissues even after multiple dosing (maximal dose 50 ml/kg), and has an improved HES safety profile in terms of coagulation and kidney function. </div>
<div class="sdl3">  </div>
<div class="sdl3">  The current study is designed to assess the efficacy, safety, and pharmaceutical economics characteristic of perioperative volume replacement with Voluven (130/0.4) in patients undergoing liver transplantation compared with patients who received volume therapy with albumin. The objective of this study is to supply appropriate regimens for patients undergoing liver transplantation, considering clinical efficacy, safety, and costs.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  End-stage liver disease is one of the major diseases leading to death. With advancement of transplantation surgery and perioperative anesthesia management, liver transplantation has become an effective method to recover patients&amp;#8217; liver function, thus saving their lives and improving their quality of life. Serious disorders of fluid balance, such as blood coagulation dysfunction, electrolyte disequilibrium, hypoalbuminaemia, low hematocrit, low hemoglobin and acid-base imbalance etc. exist in end stage cirrhosis patients with liver transplantation. Such abnormalities in the internal milieu could cause or worsen cardiovascular and pulmonary dysfunction, thus making perioperative management more difficult.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Albumin and blood plasma are conventionally used as plasma volume expanders in clinical practice. At the same time, the level of albumin concentration is also used as an important criterion of prognosis. When the level of albumin concentration in serum is below 35 g/L, postoperative mortality rates and complications will increase significantly. In fact, it has been the focus of debate for many years whether albumin should be used for volume replacement in critically ill patients. Boldt and his colleagues demonstrated that albumin has little positive influence on the prognosis of critically ill patients. However, Shwe deemed albumin beneficial to critically ill patients. Simon suggested that albumin is given mainly for treating hypovolemia instead of increasing the level of albumin concentration in serum. However, at the same time, he admitted there is no advantages of albumin in comparison to other colloid solutions and, furthermore, it is more expensive.</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">  Voluven (130/0.4) is a medium molecular weight hydroxyethyl starch (HES) produced by Beijing Fresenius Kabi Pharmaceutical Co., Ltd. It is a novel HES preparation with optimized molecular weight and molecule distribution, has a lower degree of substitution (DS) (0.4), and a narrower molecular distribution profile (C2/C6) than other available HES specifications which make it more suitable for volume replacement therapy. Some studies have revealed that Voluven (130/0.4) has a comparable efficacy with HAES-steril (average molecular weight 200.000 dalton, degree of substitution 0.5). Because of its improved pharmacological profile, Voluven (130/0.4) is used to avoid capillary vessel leakage and improve oxygenation of tissues. In addition, Voluven (130/0.4) does not accumulate in plasma or tissues even after multiple dosing (maximal dose 50 ml/kg), and has an improved HES safety profile in terms of coagulation and kidney function. </div>
<div class="sdl3">  </div>
<div class="sdl3">  The current study is designed to assess the efficacy, safety, and pharmaceutical economics characteristic of perioperative volume replacement with Voluven (130/0.4) in patients undergoing liver transplantation compared with patients who received volume therapy with albumin. The objective of this study is to supply appropriate regimens for patients undergoing liver transplantation, considering clinical efficacy, safety, and costs.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2006-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2005-10</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sds">&lt;end_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2006-10</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/end_date&gt;</div>
<div class="sdl1 sds">&lt;last_follow_up_date&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f40B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f40&#39;)" style="display:none" /><img id="sdiff-collapse-f40B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f40&#39;)" style="display:none" /><div class="sdl3">  </div>
<div id="sdiff-collapse-f40B-cdiv" class="sdiff-collapsed" title="The middle 38 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f40&#39;)" style="display:none"></div><div id="sdiff-collapse-f40B-ediv" class="sdiff-expanded"><div class="sdl3">  Albumin and blood plasma are conventionally used as plasma volume expanders in clinical practice. The focus of debate for many years has been whether albumin should be used for volume replacement in critically ill patients.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Voluven (130/0.4) is a medium molecular weight hydroxyethyl starch (HES) produced by Beijing Fresenius Kabi Pharmaceutical Co., Ltd. It is a novel HES preparation with optimized molecular weight and molecule distribution, has a lower degree of substitution (DS) (0.4), and a narrower molecular distribution profile (C2/C6) than other available HES specifications which make it more suitable for volume replacement therapy. Some studies have revealed that Voluven (130/0.4) has a comparable efficacy with HAES-steril (average molecular weight 200.000 dalton, degree of substitution 0.5). Because of its improved pharmacological profile, Voluven (130/0.4) is used to avoid capillary vessel leakage and improve oxygenation of tissues. In addition, Voluven (130/0.4) does not accumulate in plasma or tissues even after multiple dosing (maximal dose 50 ml/kg), and has an improved HES safety profile in terms of coagulation and kidney function. </div>
<div class="sdl3">  </div>
<div class="sdl3">  The current study is designed to assess the efficacy, safety, and pharmaceutical economics characteristic of perioperative volume replacement with Voluven (130/0.4) in patients undergoing liver transplantation compared with patients who received volume therapy with albumin. The objective of this study is to supply appropriate regimens for patients undergoing liver transplantation, considering clinical efficacy, safety, and costs.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  End-stage liver disease is one of the major diseases leading to death. With advancement of transplantation surgery and perioperative anesthesia management, liver transplantation has become an effective method to recover patients&amp;#8217; liver function, thus saving their lives and improving their quality of life. Serious disorders of fluid balance, such as blood coagulation dysfunction, electrolyte disequilibrium, hypoalbuminaemia, low hematocrit, low hemoglobin and acid-base imbalance etc. exist in end stage cirrhosis patients with liver transplantation. Such abnormalities in the internal milieu could cause or worsen cardiovascular and pulmonary dysfunction, thus making perioperative management more difficult.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Albumin and blood plasma are conventionally used as plasma volume expanders in clinical practice. At the same time, the level of albumin concentration is also used as an important criterion of prognosis. When the level of albumin concentration in serum is below 35 g/L, postoperative mortality rates and complications will increase significantly. In fact, it has been the focus of debate for many years whether albumin should be used for volume replacement in critically ill patients. Boldt and his colleagues demonstrated that albumin has little positive influence on the prognosis of critically ill patients. However, Shwe deemed albumin beneficial to critically ill patients. Simon suggested that albumin is given mainly for treating hypovolemia instead of increasing the level of albumin concentration in serum. However, at the same time, he admitted there is no advantages of albumin in comparison to other colloid solutions and, furthermore, it is more expensive.</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">  Voluven (130/0.4) is a medium molecular weight hydroxyethyl starch (HES) produced by Beijing Fresenius Kabi Pharmaceutical Co., Ltd. It is a novel HES preparation with optimized molecular weight and molecule distribution, has a lower degree of substitution (DS) (0.4), and a narrower molecular distribution profile (C2/C6) than other available HES specifications which make it more suitable for volume replacement therapy. Some studies have revealed that Voluven (130/0.4) has a comparable efficacy with HAES-steril (average molecular weight 200.000 dalton, degree of substitution 0.5). Because of its improved pharmacological profile, Voluven (130/0.4) is used to avoid capillary vessel leakage and improve oxygenation of tissues. In addition, Voluven (130/0.4) does not accumulate in plasma or tissues even after multiple dosing (maximal dose 50 ml/kg), and has an improved HES safety profile in terms of coagulation and kidney function. </div>
<div class="sdl3">  </div>
<div class="sdl3">  The current study is designed to assess the efficacy, safety, and pharmaceutical economics characteristic of perioperative volume replacement with Voluven (130/0.4) in patients undergoing liver transplantation compared with patients who received volume therapy with albumin. The objective of this study is to supply appropriate regimens for patients undergoing liver transplantation, considering clinical efficacy, safety, and costs.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2006-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2005-10</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sds">&lt;end_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2006-10</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/end_date&gt;</div>
<div class="sdl1 sds">&lt;last_follow_up_date&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
</tr>
<tr class="sdiff-del" id="sdiff-chunk-f4"><td class="sdiff-h">4</td>
<td class="sdiff-a"><div class="sdl3">  2006-06</div>
</td>
<td class="sdiff-b"><div class="sdl3"></div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f5"><td class="sdiff-h">5</td>
<td class="sdiff-a"><img id="sdiff-collapse-f81A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f81&#39;)" style="display:none" /><img id="sdiff-collapse-f81A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f81&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-f81A-cdiv" class="sdiff-collapsed" title="The middle 2 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f81&#39;)" style="display:none"></div><div id="sdiff-collapse-f81A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sds">&lt;last_data_entry_date&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f81B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f81&#39;)" style="display:none" /><img id="sdiff-collapse-f81B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f81&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-f81B-cdiv" class="sdiff-collapsed" title="The middle 2 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f81&#39;)" style="display:none"></div><div id="sdiff-collapse-f81B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sds">&lt;last_data_entry_date&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
</tr>
<tr class="sdiff-del" id="sdiff-chunk-f6"><td class="sdiff-h">6</td>
<td class="sdiff-a"><div class="sdl3">  2006-07</div>
</td>
<td class="sdiff-b"><div class="sdl3"></div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f7"><td class="sdiff-h">7</td>
<td class="sdiff-a"><img id="sdiff-collapse-f86A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f86&#39;)" style="display:none" /><img id="sdiff-collapse-f86A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f86&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-f86A-cdiv" class="sdiff-collapsed" title="The middle 27 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f86&#39;)" style="display:none"></div><div id="sdiff-collapse-f86A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/last_data_entry_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 4</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Active Control</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Parallel Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Safety/Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
</div><div class="sdl1 sds">&lt;primary_outcome&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f86B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f86&#39;)" style="display:none" /><img id="sdiff-collapse-f86B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f86&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-f86B-cdiv" class="sdiff-collapsed" title="The middle 27 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f86&#39;)" style="display:none"></div><div id="sdiff-collapse-f86B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/last_data_entry_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 4</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Active Control</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Parallel Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Safety/Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
</div><div class="sdl1 sds">&lt;primary_outcome&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f8"><td class="sdiff-h">8</td>
<td class="sdiff-a"><div class="sdl2"><span class="sdwc">Hemodynamics,</span> </div>
</td>
<td class="sdiff-b"><div class="sdl2"><span class="sdwc">Hemodynamics</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f9"><td class="sdiff-h">9</td>
<td class="sdiff-a"><img id="sdiff-collapse-f116A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f116&#39;)" style="display:none" /><img id="sdiff-collapse-f116A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f116&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div id="sdiff-collapse-f116A-cdiv" class="sdiff-collapsed" title="The middle 122 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f116&#39;)" style="display:none"></div><div id="sdiff-collapse-f116A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Child-Turcotte-Pugh (CTP) score</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Model for End-Stage Liver Disease (MELD) score</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Intraoperative Complications</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Hydroxyethyl Starch (130/0.4)</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">    - Aged 18-65 years, male or female</div>
<div class="sdl4">    - Elective liver transplantation</div>
<div class="sdl4">    - United Network for Organ Sharing (UNOS) Level 2A/B or 3         </div>
<div class="sdl4">    - Serum albumin &amp;#8805; 30 g/L</div>
<div class="sdl4">    - Comprehend all the procedures of this study </div>
<div class="sdl4">    - Willing and able to give informed consent</div>
<div class="sdl4">  </div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">    -  Uncontrolled exo-hepatic malignant carcinomas</div>
<div class="sdl4">    -  Uncontrollable infections (including HIV infection)</div>
<div class="sdl4">    -  Need support of artificial liver or kidney, ventilator-dependant, coma or    unstable hemodynamically</div>
<div class="sdl4">    - Patients with a history of hypersensitivity to hydroxyethyl starch or albumin</div>
<div class="sdl4">    -  Urinary output less than 500 ml within 24 hours after operation</div>
<div class="sdl4">    -  Patients with intracranial bleeding</div>
<div class="sdl4">    -  Patients with other colloids for treating hypovolemia</div>
<div class="sdl4">    -  Patients with pulmonary edema</div>
<div class="sdl4">    -  Pregnant women or females of childbearing potential and lactating mothers</div>
<div class="sdl4">    -  Patients who are participating in other drug studies or who receive other investigational drugs within 30 days prior to the present study</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;patients&gt;</div>
<div class="sdl2 sdz">&lt;/patients&gt;</div>
<div class="sdl2 sds">&lt;expected_enrollment&gt;</div>
<div class="sdl3">  200</div>
<div class="sdl2 sdz">&lt;/expected_enrollment&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  18 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  65 Years</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Xisheng Leng, MD</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  People&amp;apos;s University of Peking University</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;contact&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Fengxue Zhu, MD</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;phone&gt;</div>
<div class="sdl3">  13911005275</div>
<div class="sdl2 sdz">&lt;/phone&gt;</div>
<div class="sdl2 sds">&lt;phone_ext&gt;</div>
<div class="sdl2 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl2 sds">&lt;email&gt;</div>
<div class="sdl2 sdz">&lt;/email&gt;</div>
<div class="sdl1 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  People&amp;apos;s Hospital of Peking University</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  Beijing</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  100044</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  China</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Sub-Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Fengxue Zhu, MD</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sdz">&lt;/location&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Liver Transplantation</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2006-03-28</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f116B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f116&#39;)" style="display:none" /><img id="sdiff-collapse-f116B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f116&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div id="sdiff-collapse-f116B-cdiv" class="sdiff-collapsed" title="The middle 122 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f116&#39;)" style="display:none"></div><div id="sdiff-collapse-f116B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Child-Turcotte-Pugh (CTP) score</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Model for End-Stage Liver Disease (MELD) score</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Intraoperative Complications</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Hydroxyethyl Starch (130/0.4)</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">    - Aged 18-65 years, male or female</div>
<div class="sdl4">    - Elective liver transplantation</div>
<div class="sdl4">    - United Network for Organ Sharing (UNOS) Level 2A/B or 3         </div>
<div class="sdl4">    - Serum albumin &amp;#8805; 30 g/L</div>
<div class="sdl4">    - Comprehend all the procedures of this study </div>
<div class="sdl4">    - Willing and able to give informed consent</div>
<div class="sdl4">  </div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">    -  Uncontrolled exo-hepatic malignant carcinomas</div>
<div class="sdl4">    -  Uncontrollable infections (including HIV infection)</div>
<div class="sdl4">    -  Need support of artificial liver or kidney, ventilator-dependant, coma or    unstable hemodynamically</div>
<div class="sdl4">    - Patients with a history of hypersensitivity to hydroxyethyl starch or albumin</div>
<div class="sdl4">    -  Urinary output less than 500 ml within 24 hours after operation</div>
<div class="sdl4">    -  Patients with intracranial bleeding</div>
<div class="sdl4">    -  Patients with other colloids for treating hypovolemia</div>
<div class="sdl4">    -  Patients with pulmonary edema</div>
<div class="sdl4">    -  Pregnant women or females of childbearing potential and lactating mothers</div>
<div class="sdl4">    -  Patients who are participating in other drug studies or who receive other investigational drugs within 30 days prior to the present study</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;patients&gt;</div>
<div class="sdl2 sdz">&lt;/patients&gt;</div>
<div class="sdl2 sds">&lt;expected_enrollment&gt;</div>
<div class="sdl3">  200</div>
<div class="sdl2 sdz">&lt;/expected_enrollment&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  18 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  65 Years</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Xisheng Leng, MD</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  People&amp;apos;s University of Peking University</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;contact&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Fengxue Zhu, MD</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;phone&gt;</div>
<div class="sdl3">  13911005275</div>
<div class="sdl2 sdz">&lt;/phone&gt;</div>
<div class="sdl2 sds">&lt;phone_ext&gt;</div>
<div class="sdl2 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl2 sds">&lt;email&gt;</div>
<div class="sdl2 sdz">&lt;/email&gt;</div>
<div class="sdl1 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  People&amp;apos;s Hospital of Peking University</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  Beijing</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  100044</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  China</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Sub-Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Fengxue Zhu, MD</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sdz">&lt;/location&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Liver Transplantation</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2006-03-28</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f10"><td class="sdiff-h">10</td>
<td class="sdiff-a"><div class="sdl2"><span class="sdwc">2006-08-30</span> </div>
</td>
<td class="sdiff-b"><div class="sdl2"><span class="sdwc">2006-08-31</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f11"><td class="sdiff-h">11</td>
<td class="sdiff-a"><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
<td class="sdiff-b"><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
</tr>

</table></div><div class="sdiff-view" id="sdiff-main" style="display: block"><table class="sdiff navLinks"><colgroup><col id="h-col" /><col id="a-col" /><col id="b-col" /></colgroup><tr><th class="sdiff-h" /><th class="sdiff-a"><div class="sdiff-prev"><a href="/archive/NCT00308100/2006_08_30/changes" title="Show changes from prior version to this one"><img src="/archive/prev.gif" alt="[Previous]" width="23" height="19" /></a></div><h2>Before</h2><h3><a href="/archive/NCT00308100/2006_08_30">(Updated 2006_08_30)</a></h3></th><th class="sdiff-b"><div class="sdiff-next"><a href="/archive/NCT00308100/2008_05_01/changes" title="Show changes from this version to next one"><img src="/archive/next.gif" alt="[Next]" width="23" height="19" /></a></div><h2>After</h2><h3><a href="/archive/NCT00308100/2006_08_31">(Updated 2006_08_31)</a></h3></th></tr>
<tr class="sdiff-unc" id="sdiff-chunk-m1"><td class="sdiff-h">1</td>
<td class="sdiff-a"><img id="sdiff-collapse-m0A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><img id="sdiff-collapse-m0A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-m0A-cdiv" class="sdiff-collapsed" title="The middle 37 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none"></div><div id="sdiff-collapse-m0A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  BeijingFKP</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  Beijing Fresenius Kabi Pharmaceutical Co</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  BFP502</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT00308100</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Hydroxyethyl Starch (130/0.4) for Intravascular Volume Therapy in Liver Transplantation</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  A Multicenter, Randomized, Open-Label, Parallel-Group, Albumin-Controlled Phase IV Study to Evaluate the Efficacy and Safety of Hydroxyethyl Starch (130/0.4) for Intravascular Volume Therapy in Patients Undergoing Liver Transplantation</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Beijing Fresenius Kabi Pharmaceutical Co</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  China: State Food and Drug Administration</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
</div><div class="sdl2 sds">&lt;textblock&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m0B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><img id="sdiff-collapse-m0B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-m0B-cdiv" class="sdiff-collapsed" title="The middle 37 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none"></div><div id="sdiff-collapse-m0B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  BeijingFKP</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  Beijing Fresenius Kabi Pharmaceutical Co</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  BFP502</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT00308100</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Hydroxyethyl Starch (130/0.4) for Intravascular Volume Therapy in Liver Transplantation</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  A Multicenter, Randomized, Open-Label, Parallel-Group, Albumin-Controlled Phase IV Study to Evaluate the Efficacy and Safety of Hydroxyethyl Starch (130/0.4) for Intravascular Volume Therapy in Patients Undergoing Liver Transplantation</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Beijing Fresenius Kabi Pharmaceutical Co</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  China: State Food and Drug Administration</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
</div><div class="sdl2 sds">&lt;textblock&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m2"><td class="sdiff-h">2</td>
<td class="sdiff-a"><div class="sdl3">End-stage liver disease is one of the major diseases leading to death. Liver transplantation is an effective method to recover patients&amp;#8217; liver function, thus saving their lives and improving their quality of life. Serious disorders of fluid balance exist in <span class="sdwd">end</span> <span class="sdwd">stage</span>  cirrhosis patients undergoing liver transplantation. Such abnormalities could cause or worsen cardiovascular and pulmonary dysfunction, thus making perioperative management more difficult. </div>
</td>
<td class="sdiff-b"><div class="sdl3">End-stage  liver  disease  is  one  of  the  major  diseases  leading  to  death.  Liver  transplantation  is  an  effective  method  to  recover  patients&amp;#8217;  liver  function,  thus  saving  their  lives  and  improving  their  quality  of  life.  Serious  disorders  of  fluid  balance  exist  in    <span class="sdwa">end-stage</span> cirrhosis  patients  undergoing  liver  transplantation.  Such  abnormalities  could  cause  or  worsen  cardiovascular  and  pulmonary  dysfunction,  thus  making  perioperative  management  more  difficult.  </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m3"><td class="sdiff-h">3</td>
<td class="sdiff-a"><img id="sdiff-collapse-m40A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m40&#39;)" style="display:none" /><img id="sdiff-collapse-m40A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m40&#39;)" style="display:none" /><div class="sdl3">  </div>
<div id="sdiff-collapse-m40A-cdiv" class="sdiff-collapsed" title="The middle 38 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m40&#39;)" style="display:none"></div><div id="sdiff-collapse-m40A-ediv" class="sdiff-expanded"><div class="sdl3">  Albumin and blood plasma are conventionally used as plasma volume expanders in clinical practice. The focus of debate for many years has been whether albumin should be used for volume replacement in critically ill patients.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Voluven (130/0.4) is a medium molecular weight hydroxyethyl starch (HES) produced by Beijing Fresenius Kabi Pharmaceutical Co., Ltd. It is a novel HES preparation with optimized molecular weight and molecule distribution, has a lower degree of substitution (DS) (0.4), and a narrower molecular distribution profile (C2/C6) than other available HES specifications which make it more suitable for volume replacement therapy. Some studies have revealed that Voluven (130/0.4) has a comparable efficacy with HAES-steril (average molecular weight 200.000 dalton, degree of substitution 0.5). Because of its improved pharmacological profile, Voluven (130/0.4) is used to avoid capillary vessel leakage and improve oxygenation of tissues. In addition, Voluven (130/0.4) does not accumulate in plasma or tissues even after multiple dosing (maximal dose 50 ml/kg), and has an improved HES safety profile in terms of coagulation and kidney function. </div>
<div class="sdl3">  </div>
<div class="sdl3">  The current study is designed to assess the efficacy, safety, and pharmaceutical economics characteristic of perioperative volume replacement with Voluven (130/0.4) in patients undergoing liver transplantation compared with patients who received volume therapy with albumin. The objective of this study is to supply appropriate regimens for patients undergoing liver transplantation, considering clinical efficacy, safety, and costs.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  End-stage liver disease is one of the major diseases leading to death. With advancement of transplantation surgery and perioperative anesthesia management, liver transplantation has become an effective method to recover patients&amp;#8217; liver function, thus saving their lives and improving their quality of life. Serious disorders of fluid balance, such as blood coagulation dysfunction, electrolyte disequilibrium, hypoalbuminaemia, low hematocrit, low hemoglobin and acid-base imbalance etc. exist in end stage cirrhosis patients with liver transplantation. Such abnormalities in the internal milieu could cause or worsen cardiovascular and pulmonary dysfunction, thus making perioperative management more difficult.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Albumin and blood plasma are conventionally used as plasma volume expanders in clinical practice. At the same time, the level of albumin concentration is also used as an important criterion of prognosis. When the level of albumin concentration in serum is below 35 g/L, postoperative mortality rates and complications will increase significantly. In fact, it has been the focus of debate for many years whether albumin should be used for volume replacement in critically ill patients. Boldt and his colleagues demonstrated that albumin has little positive influence on the prognosis of critically ill patients. However, Shwe deemed albumin beneficial to critically ill patients. Simon suggested that albumin is given mainly for treating hypovolemia instead of increasing the level of albumin concentration in serum. However, at the same time, he admitted there is no advantages of albumin in comparison to other colloid solutions and, furthermore, it is more expensive.</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">  Voluven (130/0.4) is a medium molecular weight hydroxyethyl starch (HES) produced by Beijing Fresenius Kabi Pharmaceutical Co., Ltd. It is a novel HES preparation with optimized molecular weight and molecule distribution, has a lower degree of substitution (DS) (0.4), and a narrower molecular distribution profile (C2/C6) than other available HES specifications which make it more suitable for volume replacement therapy. Some studies have revealed that Voluven (130/0.4) has a comparable efficacy with HAES-steril (average molecular weight 200.000 dalton, degree of substitution 0.5). Because of its improved pharmacological profile, Voluven (130/0.4) is used to avoid capillary vessel leakage and improve oxygenation of tissues. In addition, Voluven (130/0.4) does not accumulate in plasma or tissues even after multiple dosing (maximal dose 50 ml/kg), and has an improved HES safety profile in terms of coagulation and kidney function. </div>
<div class="sdl3">  </div>
<div class="sdl3">  The current study is designed to assess the efficacy, safety, and pharmaceutical economics characteristic of perioperative volume replacement with Voluven (130/0.4) in patients undergoing liver transplantation compared with patients who received volume therapy with albumin. The objective of this study is to supply appropriate regimens for patients undergoing liver transplantation, considering clinical efficacy, safety, and costs.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2006-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2005-10</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sds">&lt;end_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2006-10</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/end_date&gt;</div>
<div class="sdl1 sds">&lt;last_follow_up_date&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m40B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m40&#39;)" style="display:none" /><img id="sdiff-collapse-m40B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m40&#39;)" style="display:none" /><div class="sdl3">  </div>
<div id="sdiff-collapse-m40B-cdiv" class="sdiff-collapsed" title="The middle 38 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m40&#39;)" style="display:none"></div><div id="sdiff-collapse-m40B-ediv" class="sdiff-expanded"><div class="sdl3">  Albumin and blood plasma are conventionally used as plasma volume expanders in clinical practice. The focus of debate for many years has been whether albumin should be used for volume replacement in critically ill patients.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Voluven (130/0.4) is a medium molecular weight hydroxyethyl starch (HES) produced by Beijing Fresenius Kabi Pharmaceutical Co., Ltd. It is a novel HES preparation with optimized molecular weight and molecule distribution, has a lower degree of substitution (DS) (0.4), and a narrower molecular distribution profile (C2/C6) than other available HES specifications which make it more suitable for volume replacement therapy. Some studies have revealed that Voluven (130/0.4) has a comparable efficacy with HAES-steril (average molecular weight 200.000 dalton, degree of substitution 0.5). Because of its improved pharmacological profile, Voluven (130/0.4) is used to avoid capillary vessel leakage and improve oxygenation of tissues. In addition, Voluven (130/0.4) does not accumulate in plasma or tissues even after multiple dosing (maximal dose 50 ml/kg), and has an improved HES safety profile in terms of coagulation and kidney function. </div>
<div class="sdl3">  </div>
<div class="sdl3">  The current study is designed to assess the efficacy, safety, and pharmaceutical economics characteristic of perioperative volume replacement with Voluven (130/0.4) in patients undergoing liver transplantation compared with patients who received volume therapy with albumin. The objective of this study is to supply appropriate regimens for patients undergoing liver transplantation, considering clinical efficacy, safety, and costs.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  End-stage liver disease is one of the major diseases leading to death. With advancement of transplantation surgery and perioperative anesthesia management, liver transplantation has become an effective method to recover patients&amp;#8217; liver function, thus saving their lives and improving their quality of life. Serious disorders of fluid balance, such as blood coagulation dysfunction, electrolyte disequilibrium, hypoalbuminaemia, low hematocrit, low hemoglobin and acid-base imbalance etc. exist in end stage cirrhosis patients with liver transplantation. Such abnormalities in the internal milieu could cause or worsen cardiovascular and pulmonary dysfunction, thus making perioperative management more difficult.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Albumin and blood plasma are conventionally used as plasma volume expanders in clinical practice. At the same time, the level of albumin concentration is also used as an important criterion of prognosis. When the level of albumin concentration in serum is below 35 g/L, postoperative mortality rates and complications will increase significantly. In fact, it has been the focus of debate for many years whether albumin should be used for volume replacement in critically ill patients. Boldt and his colleagues demonstrated that albumin has little positive influence on the prognosis of critically ill patients. However, Shwe deemed albumin beneficial to critically ill patients. Simon suggested that albumin is given mainly for treating hypovolemia instead of increasing the level of albumin concentration in serum. However, at the same time, he admitted there is no advantages of albumin in comparison to other colloid solutions and, furthermore, it is more expensive.</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">  Voluven (130/0.4) is a medium molecular weight hydroxyethyl starch (HES) produced by Beijing Fresenius Kabi Pharmaceutical Co., Ltd. It is a novel HES preparation with optimized molecular weight and molecule distribution, has a lower degree of substitution (DS) (0.4), and a narrower molecular distribution profile (C2/C6) than other available HES specifications which make it more suitable for volume replacement therapy. Some studies have revealed that Voluven (130/0.4) has a comparable efficacy with HAES-steril (average molecular weight 200.000 dalton, degree of substitution 0.5). Because of its improved pharmacological profile, Voluven (130/0.4) is used to avoid capillary vessel leakage and improve oxygenation of tissues. In addition, Voluven (130/0.4) does not accumulate in plasma or tissues even after multiple dosing (maximal dose 50 ml/kg), and has an improved HES safety profile in terms of coagulation and kidney function. </div>
<div class="sdl3">  </div>
<div class="sdl3">  The current study is designed to assess the efficacy, safety, and pharmaceutical economics characteristic of perioperative volume replacement with Voluven (130/0.4) in patients undergoing liver transplantation compared with patients who received volume therapy with albumin. The objective of this study is to supply appropriate regimens for patients undergoing liver transplantation, considering clinical efficacy, safety, and costs.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2006-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2005-10</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sds">&lt;end_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2006-10</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/end_date&gt;</div>
<div class="sdl1 sds">&lt;last_follow_up_date&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
</tr>
<tr class="sdiff-del" id="sdiff-chunk-m4"><td class="sdiff-h">4</td>
<td class="sdiff-a"><div class="sdl3">  2006-06</div>
</td>
<td class="sdiff-b"><div class="sdl3"></div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m5"><td class="sdiff-h">5</td>
<td class="sdiff-a"><img id="sdiff-collapse-m81A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m81&#39;)" style="display:none" /><img id="sdiff-collapse-m81A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m81&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-m81A-cdiv" class="sdiff-collapsed" title="The middle 2 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m81&#39;)" style="display:none"></div><div id="sdiff-collapse-m81A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sds">&lt;last_data_entry_date&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m81B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m81&#39;)" style="display:none" /><img id="sdiff-collapse-m81B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m81&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-m81B-cdiv" class="sdiff-collapsed" title="The middle 2 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m81&#39;)" style="display:none"></div><div id="sdiff-collapse-m81B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sds">&lt;last_data_entry_date&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
</tr>
<tr class="sdiff-del" id="sdiff-chunk-m6"><td class="sdiff-h">6</td>
<td class="sdiff-a"><div class="sdl3">  2006-07</div>
</td>
<td class="sdiff-b"><div class="sdl3"></div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m7"><td class="sdiff-h">7</td>
<td class="sdiff-a"><img id="sdiff-collapse-m86A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m86&#39;)" style="display:none" /><img id="sdiff-collapse-m86A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m86&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-m86A-cdiv" class="sdiff-collapsed" title="The middle 27 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m86&#39;)" style="display:none"></div><div id="sdiff-collapse-m86A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/last_data_entry_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 4</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Active Control</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Parallel Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Safety/Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
</div><div class="sdl1 sds">&lt;primary_outcome&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m86B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m86&#39;)" style="display:none" /><img id="sdiff-collapse-m86B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m86&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-m86B-cdiv" class="sdiff-collapsed" title="The middle 27 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m86&#39;)" style="display:none"></div><div id="sdiff-collapse-m86B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/last_data_entry_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 4</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Active Control</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Parallel Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Safety/Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
</div><div class="sdl1 sds">&lt;primary_outcome&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m8"><td class="sdiff-h">8</td>
<td class="sdiff-a"><div class="sdl2"><span class="sdwc">Hemodynamics,</span> </div>
</td>
<td class="sdiff-b"><div class="sdl2"><span class="sdwc">Hemodynamics</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m9"><td class="sdiff-h">9</td>
<td class="sdiff-a"><img id="sdiff-collapse-m116A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m116&#39;)" style="display:none" /><img id="sdiff-collapse-m116A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m116&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div id="sdiff-collapse-m116A-cdiv" class="sdiff-collapsed" title="The middle 79 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m116&#39;)" style="display:none"></div><div id="sdiff-collapse-m116A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Child-Turcotte-Pugh (CTP) score</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Model for End-Stage Liver Disease (MELD) score</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Intraoperative Complications</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Hydroxyethyl Starch (130/0.4)</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">    - Aged 18-65 years, male or female</div>
<div class="sdl4">    - Elective liver transplantation</div>
<div class="sdl4">    - United Network for Organ Sharing (UNOS) Level 2A/B or 3         </div>
<div class="sdl4">    - Serum albumin &amp;#8805; 30 g/L</div>
<div class="sdl4">    - Comprehend all the procedures of this study </div>
<div class="sdl4">    - Willing and able to give informed consent</div>
<div class="sdl4">  </div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">    -  Uncontrolled exo-hepatic malignant carcinomas</div>
<div class="sdl4">    -  Uncontrollable infections (including HIV infection)</div>
<div class="sdl4">    -  Need support of artificial liver or kidney, ventilator-dependant, coma or    unstable hemodynamically</div>
<div class="sdl4">    - Patients with a history of hypersensitivity to hydroxyethyl starch or albumin</div>
<div class="sdl4">    -  Urinary output less than 500 ml within 24 hours after operation</div>
<div class="sdl4">    -  Patients with intracranial bleeding</div>
<div class="sdl4">    -  Patients with other colloids for treating hypovolemia</div>
<div class="sdl4">    -  Patients with pulmonary edema</div>
<div class="sdl4">    -  Pregnant women or females of childbearing potential and lactating mothers</div>
<div class="sdl4">    -  Patients who are participating in other drug studies or who receive other investigational drugs within 30 days prior to the present study</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;patients&gt;</div>
<div class="sdl2 sdz">&lt;/patients&gt;</div>
<div class="sdl2 sds">&lt;expected_enrollment&gt;</div>
<div class="sdl3">  200</div>
<div class="sdl2 sdz">&lt;/expected_enrollment&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  18 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  65 Years</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Xisheng Leng, MD</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  People&amp;apos;s University of Peking University</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Liver Transplantation</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2006-03-28</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m116B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m116&#39;)" style="display:none" /><img id="sdiff-collapse-m116B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m116&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div id="sdiff-collapse-m116B-cdiv" class="sdiff-collapsed" title="The middle 79 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m116&#39;)" style="display:none"></div><div id="sdiff-collapse-m116B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Child-Turcotte-Pugh (CTP) score</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Model for End-Stage Liver Disease (MELD) score</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Intraoperative Complications</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Hydroxyethyl Starch (130/0.4)</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">    - Aged 18-65 years, male or female</div>
<div class="sdl4">    - Elective liver transplantation</div>
<div class="sdl4">    - United Network for Organ Sharing (UNOS) Level 2A/B or 3         </div>
<div class="sdl4">    - Serum albumin &amp;#8805; 30 g/L</div>
<div class="sdl4">    - Comprehend all the procedures of this study </div>
<div class="sdl4">    - Willing and able to give informed consent</div>
<div class="sdl4">  </div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">    -  Uncontrolled exo-hepatic malignant carcinomas</div>
<div class="sdl4">    -  Uncontrollable infections (including HIV infection)</div>
<div class="sdl4">    -  Need support of artificial liver or kidney, ventilator-dependant, coma or    unstable hemodynamically</div>
<div class="sdl4">    - Patients with a history of hypersensitivity to hydroxyethyl starch or albumin</div>
<div class="sdl4">    -  Urinary output less than 500 ml within 24 hours after operation</div>
<div class="sdl4">    -  Patients with intracranial bleeding</div>
<div class="sdl4">    -  Patients with other colloids for treating hypovolemia</div>
<div class="sdl4">    -  Patients with pulmonary edema</div>
<div class="sdl4">    -  Pregnant women or females of childbearing potential and lactating mothers</div>
<div class="sdl4">    -  Patients who are participating in other drug studies or who receive other investigational drugs within 30 days prior to the present study</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;patients&gt;</div>
<div class="sdl2 sdz">&lt;/patients&gt;</div>
<div class="sdl2 sds">&lt;expected_enrollment&gt;</div>
<div class="sdl3">  200</div>
<div class="sdl2 sdz">&lt;/expected_enrollment&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  18 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  65 Years</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Xisheng Leng, MD</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  People&amp;apos;s University of Peking University</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Liver Transplantation</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2006-03-28</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m10"><td class="sdiff-h">10</td>
<td class="sdiff-a"><div class="sdl2"><span class="sdwc">2006-08-30</span> </div>
</td>
<td class="sdiff-b"><div class="sdl2"><span class="sdwc">2006-08-31</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m11"><td class="sdiff-h">11</td>
<td class="sdiff-a"><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
<td class="sdiff-b"><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
</tr>

</table></div></form><div class="navBottom"><div class="navBottomLine" style="background-image: url(/archive/ctgov_logo_ttm.gif)">&#160;</div><div class="navBottomLinks">&#160;</div></div><script>
SDiffDeclareUnchCRID('sdiff-collapse-f0');
SDiffDeclareUnchCRID('sdiff-collapse-f116');
SDiffDeclareUnchCRID('sdiff-collapse-f40');
SDiffDeclareUnchCRID('sdiff-collapse-f81');
SDiffDeclareUnchCRID('sdiff-collapse-f86');
SDiffDeclareUnchCRID('sdiff-collapse-m0');
SDiffDeclareUnchCRID('sdiff-collapse-m116');
SDiffDeclareUnchCRID('sdiff-collapse-m40');
SDiffDeclareUnchCRID('sdiff-collapse-m81');
SDiffDeclareUnchCRID('sdiff-collapse-m86');
SDiffInit();
</script></body></html>